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Comparison of PCI Procedure and Outcomes in Patients with STEMI
(Differences in TIMI Risk Score)
Hiroya Takafuji, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito,
Hiroshi Ishimori, Keisuke Hirano, Masatsugu Nakano, Motoharu Araki, Tamon Kato,
Norihiro Kobayashi, Hideyuki Takimura, Yasunari Sakamoto, Shinsuke Mori,
Masakazu Tsutsumi, Takuro Takama, Takahiro Tokuda, Kenji Makino
Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
Background: TIMI Risk score for STEMI is a convenient,bedside, clinical score
for risk assessment. However, it is not well known the difference between PCI
procedure. The purpose of this study was to assess the PCI procedure and out-
comes in patients with STEMI whether there is a difference in three TIMI Risk
Score groups: low risk (0-4points), intermediate risk (5-7points) and high risk
(8points and over).
Methods: From April 2007 to March 2013, we analyzed total 400 patients with
STEMI expect for cases of cardiopulmonary arrest on arrival and surgical treatment,
stent thrombosis, in hospital case.
Results: Complex culprit lesion cases rate had more high risk group such as ostial
lesion (low 5.6% vs. intermediate 5.6% vs. high 19.3%, p¼0.0004), bifurcation lesion
(low 8.5% vs. intermediate 14.9% vs. high 18.1%, p¼0.05), left main lesion (low 0%
vs. intermediate 1.4% vs. high 9.6%, p<0.0001), usage of intra aortic balloon pump
(IABP) (low 9.6% vs. intermediate 11.3% vs. high 38.5%, p<0.0001). In-hospital
mortality was high rate in high risk group (low 1.2% vs. intermediate 4.9% vs. high
16.8%, p<0.0001). There was a statistically signiﬁcant difference in survival between
all risk groups in 30-days and one-year follow-up (Log rank p<0.0001). Outcome
rates at 2 year follow up for TLR free MACCE (All cause death, myocardial
infarction, stroke) using the Kaplan-Meier methods were low 7.2% vs. intermediate
17.5% vs. high 29.5% (Log rank p<0.0001).
Conclusion: The higher TIMI risk score,the rate of complex lesions such as LMCA,
bifurcation and ostial is higher and prognosis is poor.
TCTAP A-023
Impact of Different Subtypes of Microvascular Dysfunction on Myocardial
Strains in ST-segment Elevation Myocardial Infarction Patients Treated with
Reperfusion Therapy
Heng Ge, Hang Zhao, Zheng Li, Weiming Chai, Xin Ge, Zizhou Zhao, Li Zhu, Jun Pu,
Jianrong Xu, Xuedong Shen
Renji hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background: Presence of microvascular dysfunction (MD) has been regarded as a
key prognostic factor for ST-segment Elevation Myocardial Infarction (STEMI) pa-
tients who received reperfusion therapy. Cardiac Magnetic Resonance Imaging
(CMR) can differentiate subtypes of MD, i.e. solo microvascular obstruction (MVO)
or MVO with intramyocardial hemorrhage (IMH), which theoretically have different
effects on myocardial movements in infarction zone. This study aimed to disclose the
relationship between subtypes of MD and changes of myocardial strain in reperfused
STEMI patients.
Methods: Sixty-three STEMI patients who received primary percutaneous coro-
nary intervention within 12 hours form the basis of this study. MD and its sub-
types were deﬁned by CMR using T2-weighted and late-gadolinium-enhancement
imaging technologies within 1 week after STEMI onset for each patient.
Myocardial strains were measured on the same day of the CMR examination by
2D쭯speckle-tracking echocardiography (2DSTE), where peak systolic segmental
circumferential (CS), radial (RS), and longitudinal (LS) strains were calculated,
respectively.
Results: A total of 1134 segments were measured by 2DSTE. An infarction necrosis
with more than 50% transmural percentage caused signiﬁcant decreasing of
myocardial strain compared to normal myocardium in all three dimensions (C.S.
10.1620.15 v.s 20.157.50; RS.18.5213.88 v.s 39.072.54; LS.7.677.27 v.s
17.106.57, p< 0.001 in all comparisons). The existence of solo MVO had a trend to
further decrease the strains circumferentially and longitudinally compared to necrotic
segments without MD (CS. 7.997.21 v.s 10.1620.15; LS. 5.817.67 v.s
7.677.27, both p>0.05). However, when MVO was accompanied with IMH, the
deterioration of the strains became signiﬁcantly worse in this two dimensions (CS
4.298.96 v.s 10.1620.15; LS 4.126.66 v.s 7.677.27, both p<0.001).
Conclusion: The existence of MD, especially IMH can cause remarkably exacerba-
tion of the myocardial movement on the basis of the infarction, which can explain the
worse prognosis in this subgroup of patients as observed by former studies.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORATCTAP A-024
Prognostic Features Associated with Ischemic Preconditioning in Patients
Presenting with Acute Myocardial Infarction: Results from a Tunisian Registry
Waild Jomaa, Ikram Chamtouri, Sonia Hamdi, Mohamed Ali Azaiez,
Khaldoun Ben Hamda, Faouzi Maatouk
Fattouma Bourguiba University Hospital, Monastir, Tunisia
Background: When occurring before a myocardial infarction, ischemic pre-
conditioning is associated with lesser infarct size in animals. In humans, prognostic
signiﬁcance of ischemic episodes preceding acute myocardial infarction (AMI) is not
well understood. We sought to study prognostic features associated with ischemic
preconditioning in patients admitted for AMI.
Methods: We retrospectively reviewed data from a Tunisian registry including 1386
patients hospitalized in our center for AMI between january 1998 and january 2012
and treated either by thrombolysis, primary percutaneous coronary intervention or
conservative therapy. The overall population was divided into Preconditioning Group
and Inaugural Group according to the occurrence of symptomatic ischemic episodes
in the 24 hours preceding the AMI or not. Population characteristics and prognostic
features were compared in the two groups.
Results: Out of the study population, 383 (27.6%) patients were part of the Pre-
conditioning Group. Compared with the patients in the Inaugural Group, patients in
the Preconditioning Group had more frequently arterial hypertension (35.2% vs. 28%,
p¼0.011), diabetes mellitus (40.5% vs. 33.5%, p¼0.012) and a history of coronary
artery disease (CAD) (18.3% vs. 8%, p<0.0001). The recourse to inotropic agents for
low output was signiﬁcantly lower in the Preconditioning Group (13.3% vs. 15.2%,
p¼0.015) and in-hospital mortality was lower compared to that in the Inaugural
Group (6.3% vs. 10.1%, p¼0.028). No signiﬁcant difference could be identiﬁed be-
tween the two groups regarding age, gender, occurrence of ventricular arrhythmias
and angina recurrence. In multivariate analysis, features independently associated with
ischemic preconditioning were a history of CAD (HR: 2.38, 95% CI: 1.66-3.33,
p<0.0001) and diabetes mellitus (HR: 1.34, 95% CI: 1.04-1.71, p¼0.021). The
absence of ischemic preconditioning was independently associated to in-hospital death
(HR: 0.52, 95% CI: 0.3-0.9, p¼0.02).
Conclusion: In our study, ischemic preconditioning is independently related to dia-
betes and a history of CAD. The absence of ischemic preconditioning is independently
related to in-hospital death in patients admitted for AMI.
TCTAP A-025
A New Risk Score to Predict Bleeding Events in ST Elevation Myocardial
Infarction Patients Underwent Primary Percutaneous Coronary Intervention
Wishnu Aditya Widodo1, Sunarya Soerianata1, Andang Joesoef1, Pandu Riono2
1Cardiovascular Hospital Harapan Kita, Jakarta, Indonesia, 2Universitas Indonesia,
Jakarta, Indonesia
Background: Acute Coronary Syndrome with ST-Elevation Myocardial Infarction
(STEMI) has high mortality rate, and it is greatly increased when bleeding events
occur. Standard management of STEMI also increase the possibility of bleeding. Early
identiﬁcation of patients with high risk of bleeding is important for optimization of
STEMI care.
Methods: A retrospective cohort study, done in National Cardiovascular Center
Harapan Kita, Indonesia in STEMI patients underwent primary PCI. Bleeding event
was deﬁned with deﬁnition from Bleeding Academic Research Consortium (BARC).
Risk score was created by assignment of variables that included in the ﬁnal model
according to their Odds Ratio (OR) values.
Results: 579 samples ﬁt the inclusion and exclusion criteria. Bleeding events occurred
in 42 patients (7.3%). The complete variables included are: Female gender, Killip
class 3/4, age  62 y.o, white blood cell >12.000, creatinine >1.5, body mass index
 25, multiple coronary lesion, femoral access, and temporary pace maker (TPM)
implantation. These variables are converted into two types of scoring system; the
complete and the alternative model. Complete model contains all of the variables, and
alternative model discards variables related to interventional procedures for early
stratiﬁcation before pci. Area under the ROC curves are 0.82 and 0.84, respectively.
For each scoring system, four categories (low, moderate, high, and very high) were
made according to increased bleeding probability.
Conclusion: A new scoring system quantiﬁes risk for in-hospital bleeding events in
STEMI patients undergoing primary PCI, which might be able to enhance baseline
risk assessment for STEMI care.
TCTAP A-026
Role of Coronary Collateral Circulation in Myocardial Infarct Size in
ST-segment Elevation Myocardial Infarction Patients Underwent Primary
Percutaneous Coronary Intervention
Ika Dhanudibroto1, Sunarya Soerianata1, Manoefris Kasim1, Pandu Riono2
1National Cardiac Centre Harapan Kita, Jakarta, Indonesia, 2University of
Indonesia, University of Indonesia, Indonesia
Background: Primary percutaneous coronary intervention (PPCI) conducted imme-
diately by an expert operator is a primary reperfusion strategy in acute ST-segment
elevation myocardial infarction (STEMI) patient. Although fully aware of the
importance of early diagnosis and reperfusion in patients with STEMI, time delays areL/Acute Coronary Syndrome: STEMI, NSTE-ACS S7
often unavoidable. During this period, coronary collateral circulation be an important
alternative supply when the main blood vessels fail to provide adequate perfusion to
myocardial tissues due to occlusion. This study aims to determine the effect of
collateral circulation in MR Imaging-Veriﬁed Myocardial infarct size and myocardial
salvage index (MSI) in the acute phase of STEMI treated with PPCI.
Methods: Study was designed as cross-sectional study involving 33 STEMI patients
with symptoms < 12 hours who underwent successful PPCI. Samples were taken
consecutively from November 2012 to April at the National Cardiovascular Center
Harapan Kita Jakarta. Collateral ﬂow was gradded regarding to Rentrop classiﬁcation.
Patients were divided into 2 groups; Group A had absent or weak collateral ﬂow and
group B had signiﬁcant ﬂow. All patients underwent cardiac magnetic resonance
(CMR) to assess infarct size and MSI.
Results: In our study, 12out of 33 (36%) patients had signiﬁcant collateral circulation
(Rentrop grade2 or 3). Pre-infarction angina was a clinicalfactors associated with
recruitable collaterals(p<0,001). Infarct size expressed as percent LV mass (IS%LV)
was signiﬁcantly smaller in group B (14.2%vs. 23.3%; p ¼ 0.036). Extent of MSI was
signiﬁcantly higher in group B (0,6 vs 0,1; p<0,001).
Conclusion: Well-developed collaterals before reperfusion by PPCI in patients with
STEMI are associated with a protective effect on infarct size and MSI.
Antiplatelet Agents and Anticoagulants
(TCTAP A-027 to TCTAP A-036)
TCTAP A-027
Comparison of On-treatment Platelet Reactivity After One-month Use of
Clopidogrel, Prasugrel or Ticagrelor in Koreans with Acute Coronary
Syndromes
Ji Hyun Lee, Sung Gyun Ahn, Jun-Won Lee, Young Jin Youn, Min-Soo Ahn,
Jang-Young Kim, Byung-Su Yoo, Seung-Hwan Lee, Junghan Yoon
Wonju Severance Christian Hospital, Wonju, Korea (Republic of)
Background: Prasugrel and ticagrelor have greater anti-ischemic efﬁcacy than clo-
pidogrel, but they are not widely used in East Asia owing to their increased risk of
bleeding. We compared on-treatment platelet reactivity (OPR) of these 3 drugs after 1
month in patients with acute coronary syndromes (ACS).
Methods:We assigned 95 patients undergoing percutaneous coronary intervention for
ACS to clopidogrel, prasugrel, or ticagrelor treatment. We measured OPR using the
VerifyNow P2Y12 assay. High OPR (HOPR) was deﬁned by P2Y12 reaction unit
(PRU) 240; low OPR (LOPR) was deﬁned by PRU <85. We compared the numbers
of patients with HOPR and LOPR after 1 month of antiplatelet treatment.
Results: OPR was lowest in the ticagrelor group (n¼25), followed by the pra-
sugrel (n¼34) and clopidogrel groups (n¼36, 4930 vs 8659 vs 17977,
p <0.001). HOPR was not noted in the prasugrel or ticagrelor groups, but was
noted in 5 clopidogrel-treated patients (13.9%, p¼0.007). The ticagrelor group
had the most number of patients with LOPR, followed by the prasugrel and
clopidogrel groups (88% vs 52.9% vs 13.9%, p <0.001). The clopidogrel
group had the highest number of patients in the therapeutic window of OPR (PRU
85–239) (Figure).
Conclusion: HOPR to clopidogrel can be overcome by using prasugrel or ticagrelor.
However, prasugrel or ticagrelor increased LOPR, which may lead to excessive
bleeding events in East Asians.
TCTAP A-028
Comparison of Platelet Aggregation Before & After Loading Dose of Prasugrel
and Clopidogrel in Percutaneous Coronary Intervention in Adult Pakistani
Coronary Artery Disease Patients
Ahmad Shahbaz1, Ahmad Nouman1, Khawar Mehdi2, Muhammad Azhar1
1PIC, Karachi, Pakistan, 2Getz Pharma, Karachi, Pakistan
Background: The use of dual antiplatelet therapy with aspirin and a thienopyridine is an
essential aspect of the supportive pharmacologic regimen administered to coronary artery
disease (CAD) patients who are undergoing primary percutaneous coronary intervention
(PCI). This study was carried out to compare the inhibition of platelet aggregation (IPA)
between prasugrel and clopidogrel in adult Pakistani patients undergoing primary PCI.
Methods: A total of hundred subjects were randomly assigned to two groups A & B.
GroupA (n¼50) received prasugrel (PRISA) 60mg loading dose pre PCI and 10mgQD
maintenance dose, whereas group B (n¼50) received clopidogrel 600mg loading and 75
mg BID maintenance dose respectively. Adenosine diphospahte (ADP) was used as
agonist before loading dose and post-PCI at 3-4 hours since it is themost commonly used
agonist, particularly in systems that measure only platelet aggregation in whole blood.
Results: Male and female ratio was 4:1 in both groups. Mean age was insigniﬁcant
between group A and group B (50.39.6 vs. 50.310.9; range: 29-68 and 23-71 years
respectively). In Group A (Prasugrel) n¼50; the respective occurrence of CAD was:
LAD n¼25 (50%), RCA n¼14 (28%), Cx Distal n¼5 (10%), MVD n¼3 (6%), Non-
stent 1 (2%) & others n¼2 (4%). In Group B (Clopidogrel) n¼50; the respective
occurrence of CADwas: LAD n¼23 (46%), RCA n¼11 (22%),MVD n¼8 (16%)&Cx
Distal n¼7 (14%) & others n¼1 (2%). None of the patient experienced minor or major
adverse cardiac events after taking loading dose in both groups. The before and after
loading dose mean platelet aggregation (MPA) responses were statistically signiﬁcant
within the two treatment groups (Group A: 6.082.12 vs 1.562.11; p<0.001 and
Group B: 4.272.06 vs 0.681.38; p<0.001). The mean reduction in platelet aggre-
gation by Group A (Prasugrel) was 74.4% and by Group B (Clopidogrel) was 51.8%.
Conclusion: Prasugrel 60 mg loading dose (PRISA) achieves signiﬁcantly greater
IPA as compared to clopidogrel 600 mg LD. Both drugs were well-tolerated and
adverse drug reactions were comparable.
TCTAP A-029
Low Dose Proton Pump Inhibitors in Patients Treated with Dual-antiplatelet
Therapy After Acute Coronary Syndrome
Yoshiki Nagata, Takuya Mayumi, Tomoya Harada, Masaki Kinoshita,
Isao Aburadani, Motoaki Hirazawa, Michiro Maruyama, Kazuo Usuda
Toyama Prefectural Central Hospital, Toyama, Japan
Background: The proton pump inhibitors (PPIs) with aspirin and clopidogrel are
frequently concomitantly used to prevent adverse gastrointestinal effects. However, it has
been reported that the antiplatelet action becomes attenuated when a PPI is used in com-
bination with clopidogrel. The Food and Drug Administration issued a warning against the
concomitant use of high dose (40 mg) esomeprazole/omeprazole with clopidogrel. This
warning has raised concerns that the addition of a PPI to clopidogrel in acute coronary
syndrome (ACS)patients could actually increase the risk of recurrent cardiovascular events.
Methods: The effect of PPIs causing platelet aggregation during the administration of
clopidogrel was investigated after primary percutaneous coronary intervention (PCI).
The subjects consisted of 122 cases of ACS. Platelet aggregation function testing
(light transmission intensity method) was conducted while aspirin and clopidogrel
75mg were orally taken before discharge. The minimum concentration of aggregation
induction (Platelet aggregation threshold index; PATI) was measured. The PATI,
measured with ADP as the inducing substance, was compared and investigated ac-
cording to the type of concomitantly used PPIs.
Results: The result of the PATI were: non-PPI group: 3.730.62 mM (N¼18) and PPI
group: 3.330.94mM (N¼104). The difference of type of PPI were rabeprazole (10
mg) group: 3.630.63 mM (N¼20), esomeprazole (20 mg) group 3.310.93 (N¼39)
and lansoprazole (15 mg) group: 3.211.06 mM (N¼42). The omeprazole group was
excluded, because the subjects were only 3 cases. The PATI of lansoprazole group
was the lower than the other groups (p <0.05 compared with non-PPI group).
Conclusion: The effect of CYP2C19 differs depending on the type of PPI, with a
difference being caused in the interaction with clopidogrel. The concomitant use of
low dose lansoprazole reduced the antiplatelet action of clopidogrel. The low dose
esomeprazole reduced the antiplatelet action, but the interaction effect was small.
Rabeprazole was least inﬂuence on the antiplatelet action. When PPI is used in
combination with dual-antiplatelet therapy in ACS patients, low dose esomeprazole
and rabeprazole should be consideration.
TCTAP A-030
Safety and Efﬁcacy of a Hybrid Dual Antiplatelet Therapy Regimen for ST-
elevation Myocardial Infarction Patients: A Single-centre Experience
Deanna Khoo, Yee May Wong, Hee Hwa Ho, Yau Wei Ooi, Paul Jau, Lueng Ong,
Fahim Haider Jafary, Kwok Kong Loh, Julian Tan, David Foo
Tan Tock Seng Hospital, Singapore, Singapore
Background: Prasugrel, a third generation thienopyridine is recognised as one of the
cornerstone treatment of contemporary dual antiplatelet therapy (DAPT) in selected
patients with ST- elevation myocardial infarction (STEMI) undergoing primary
percutaneous coronary intervention (PPCI). The incremental cost of prasugrel coupled
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